Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

Area of Science:

• Oncology
• Genomics
• Immunotherapy

Background:

• Immune checkpoint inhibitors, such as anti-PD-1 antibodies, offer significant benefits for various cancers.
• However, not all patients respond to anti-PD-1 therapy, and some experience adverse effects.
• Understanding the genetic factors influencing patient response is crucial for optimizing cancer treatment.

Observation:

• An endometrial cancer patient exhibited an exceptional response to the anti-PD-1 antibody pembrolizumab.
• Genomic profiling of the patient's tumor revealed a mutation in DNA polymerase epsilon (POLE).
• This POLE mutation was associated with an ultramutator phenotype.

Findings:

• Analysis of The Cancer Genome Atlas (TCGA) data indicated that POLE mutations correlate with a high tumor mutational burden.
• POLE mutations were also linked to increased expression of immune checkpoint genes.
• These findings suggest a strong association between POLE mutations and heightened immune activity within tumors.

Implications:

• Cancers with POLE mutations may be particularly responsive to immune checkpoint inhibitor therapy.
• Genomic assessment for POLE mutations could help identify patients likely to benefit from immunotherapy.
• This research highlights the potential of precision medicine in guiding cancer treatment decisions.